Pasithea Therapeutics Corp (KTTA)

$0.71 -0.01 (-1.39%)
Market Cap 5.35M
Revenue (ttm) 0.00
Net Income (ttm) -13.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 32,900
Avg Vol 129,122
Day's Range N/A - N/A
Shares Out 7.44M
Stochastic %K 19%
Beta 0.27
Analysts Strong Buy
Price Target $2.00

Company Profile

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, inclu...

Industry: Biotechnology
Sector: Healthcare
Phone: 786 977 3380
Address:
1111 Lincoln Road, Suite 500, Miami Beach, United States
UtahSUV
UtahSUV Oct. 26 at 1:59 AM
$TZROP $RIVN $LCID $KTTA $LGVN i just want to say fuck all of these stupid tickers. Thank you and have a pleasant Saturday
0 · Reply
Zen_Trades
Zen_Trades Oct. 19 at 8:45 PM
This reasoned take on why $BCG is a candidate for a move of 100% or greater is so succinct I was tempted to plagiarize it. Instead I will leave it here. Curious to look into two tickers named in this post now,Taking a few minutes to thumb through $MBOT filings as well as $KTTA to possibly add to next week's watch. https://x.com/BillCTrades/status/1980005121615712545
1 · Reply
topstockalerts
topstockalerts Oct. 9 at 8:25 PM
After Hours Top Gainers PT2 $BGMS $LICN $SGBX $KTTA $JAGX
0 · Reply
SurfTheTicker
SurfTheTicker Oct. 7 at 3:04 AM
$AGMH $BBLG $KTTA $MSN $TBH This has been going huge so far! Watch PRHI as well, that one can be a $1 To $10 stock easily
0 · Reply
FlowRicky
FlowRicky Oct. 5 at 9:34 AM
$KTTA Biotech speculation. Pre-revenue stage. Chart shows high volatility. No clear direction.
0 · Reply
UtahSUV
UtahSUV Sep. 30 at 5:11 AM
$LGVN $KTTA i just want to say fuck you both
0 · Reply
UtahSUV
UtahSUV Sep. 22 at 5:27 PM
$KTTA to zero
0 · Reply
SPYmyQQQ
SPYmyQQQ Sep. 22 at 12:02 PM
🚨 New Signal ✅ 💊 $KTTA 🗓️ Sep 22, 2025 💵 Entry: $0.7296 🎯 Target (Optional): $0.861 (+18.01%)
0 · Reply
SurfTheTicker
SurfTheTicker Sep. 21 at 10:09 PM
$AGMH $10 $TBH $3 $BBLG $4 $KTTA $5+ $MSN $2
1 · Reply
AttractDontChase
AttractDontChase Sep. 21 at 7:38 PM
$KTTA is a rare small cap biotech trading under $1 with a prior high near $7.50, a tiny float, and real catalysts in motion. With PAS-004 in trials, global expansion, and a stronger advisory board, the setup is rock-bottom undervaluation. If data or sentiment flips, KTTA has the ingredients to be one of those rare names that re rates into the $20–$50+ zone.
0 · Reply
Latest News on KTTA
Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

Sep 16, 2025, 7:03 AM EDT - 6 weeks ago

Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 29, 2025, 8:39 AM EDT - 2 months ago

Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

Jul 31, 2025, 7:01 AM EDT - 3 months ago

Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board

Jun 11, 2025, 7:02 AM EDT - 4 months ago

Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board

Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025

Jun 2, 2025, 8:02 AM EDT - 5 months ago

Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025

Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases

May 20, 2025, 7:01 AM EDT - 5 months ago

Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases

Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site

May 14, 2025, 7:02 AM EDT - 5 months ago

Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site

Pasithea Therapeutics Announces Closing of $5 Million Public Offering

May 7, 2025, 5:00 PM EDT - 6 months ago

Pasithea Therapeutics Announces Closing of $5 Million Public Offering

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering

May 6, 2025, 11:10 AM EDT - 6 months ago

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering

Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results

May 6, 2025, 9:29 AM EDT - 6 months ago

Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results

Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004

May 6, 2025, 7:03 AM EDT - 6 months ago

Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Apr 29, 2025, 7:02 AM EDT - 6 months ago

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Apr 24, 2025, 7:02 AM EDT - 6 months ago

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Apr 10, 2025, 7:02 AM EDT - 7 months ago

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Feb 5, 2025, 6:59 AM EST - 9 months ago

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

Jan 14, 2025, 8:02 AM EST - 10 months ago

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 26, 2024, 6:44 PM EDT - 1 year ago

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Why Is Pasithea Therapeutics Stock Surging On Thursday?

Sep 26, 2024, 8:56 AM EDT - 1 year ago

Why Is Pasithea Therapeutics Stock Surging On Thursday?

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Sep 26, 2024, 7:02 AM EDT - 1 year ago

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies

Sep 9, 2024, 8:01 AM EDT - 1 year ago

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

Sep 3, 2024, 8:02 AM EDT - 1 year ago

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 28, 2024, 9:11 AM EDT - 1 year ago

Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting

May 28, 2024, 6:59 AM EDT - 1 year ago

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Apr 29, 2024, 7:59 AM EDT - 1 year ago

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers

Apr 24, 2024, 7:59 AM EDT - 1 year ago

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

Feb 13, 2024, 7:59 AM EST - 1 year ago

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

Jan 8, 2024, 7:59 AM EST - 1 year ago

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients

Jan 2, 2024, 8:35 AM EST - 1 year ago

Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients

Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023

Dec 28, 2023, 5:00 PM EST - 1 year ago

Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023

Pasithea Therapeutics Announces Results from 2023 Annual Meeting

Dec 19, 2023, 5:19 PM EST - 2 years ago

Pasithea Therapeutics Announces Results from 2023 Annual Meeting

Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models

Dec 11, 2023, 8:01 AM EST - 2 years ago

Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models

Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

Nov 29, 2023, 4:27 PM EST - 2 years ago

Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development

Nov 29, 2023, 7:59 AM EST - 2 years ago

Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

Nov 9, 2023, 7:59 AM EST - 2 years ago

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

Pasithea Therapeutics Corp. Announces Final Results of Tender Offer

Sep 14, 2023, 8:30 AM EDT - 2 years ago

Pasithea Therapeutics Corp. Announces Final Results of Tender Offer

Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference

Sep 7, 2023, 4:14 PM EDT - 2 years ago

Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference

Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved surviv

Aug 1, 2023, 7:59 AM EDT - 2 years ago

Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved surviv

Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash

Jul 20, 2023, 8:43 AM EDT - 2 years ago

Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash

Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.

Jul 20, 2023, 8:40 AM EDT - 2 years ago

Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.

Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors

Jun 30, 2023, 9:28 AM EDT - 2 years ago

Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors

Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc.

Jun 6, 2023, 4:30 PM EDT - 2 years ago

Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc.

Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference

Jun 1, 2023, 7:57 AM EDT - 2 years ago

Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference

Pasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference

May 3, 2023, 8:26 AM EDT - 2 years ago

Pasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P.

Feb 23, 2023, 8:00 AM EST - 2 years ago

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P.

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Award

Feb 16, 2023, 7:30 AM EST - 2 years ago

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Award

Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004

Jan 18, 2023, 8:00 AM EST - 3 years ago

Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004

Majority of Stockholders Support Pasithea Directors at Special Meeting

Dec 14, 2022, 5:18 PM EST - 3 years ago

Majority of Stockholders Support Pasithea Directors at Special Meeting

Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group

Dec 12, 2022, 7:00 AM EST - 3 years ago

Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group

Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics

Dec 7, 2022, 4:00 PM EST - 3 years ago

Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics

Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference

Dec 6, 2022, 8:00 AM EST - 3 years ago

Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference

UtahSUV
UtahSUV Oct. 26 at 1:59 AM
$TZROP $RIVN $LCID $KTTA $LGVN i just want to say fuck all of these stupid tickers. Thank you and have a pleasant Saturday
0 · Reply
Zen_Trades
Zen_Trades Oct. 19 at 8:45 PM
This reasoned take on why $BCG is a candidate for a move of 100% or greater is so succinct I was tempted to plagiarize it. Instead I will leave it here. Curious to look into two tickers named in this post now,Taking a few minutes to thumb through $MBOT filings as well as $KTTA to possibly add to next week's watch. https://x.com/BillCTrades/status/1980005121615712545
1 · Reply
topstockalerts
topstockalerts Oct. 9 at 8:25 PM
After Hours Top Gainers PT2 $BGMS $LICN $SGBX $KTTA $JAGX
0 · Reply
SurfTheTicker
SurfTheTicker Oct. 7 at 3:04 AM
$AGMH $BBLG $KTTA $MSN $TBH This has been going huge so far! Watch PRHI as well, that one can be a $1 To $10 stock easily
0 · Reply
FlowRicky
FlowRicky Oct. 5 at 9:34 AM
$KTTA Biotech speculation. Pre-revenue stage. Chart shows high volatility. No clear direction.
0 · Reply
UtahSUV
UtahSUV Sep. 30 at 5:11 AM
$LGVN $KTTA i just want to say fuck you both
0 · Reply
UtahSUV
UtahSUV Sep. 22 at 5:27 PM
$KTTA to zero
0 · Reply
SPYmyQQQ
SPYmyQQQ Sep. 22 at 12:02 PM
🚨 New Signal ✅ 💊 $KTTA 🗓️ Sep 22, 2025 💵 Entry: $0.7296 🎯 Target (Optional): $0.861 (+18.01%)
0 · Reply
SurfTheTicker
SurfTheTicker Sep. 21 at 10:09 PM
$AGMH $10 $TBH $3 $BBLG $4 $KTTA $5+ $MSN $2
1 · Reply
AttractDontChase
AttractDontChase Sep. 21 at 7:38 PM
$KTTA is a rare small cap biotech trading under $1 with a prior high near $7.50, a tiny float, and real catalysts in motion. With PAS-004 in trials, global expansion, and a stronger advisory board, the setup is rock-bottom undervaluation. If data or sentiment flips, KTTA has the ingredients to be one of those rare names that re rates into the $20–$50+ zone.
0 · Reply
AttractDontChase
AttractDontChase Sep. 20 at 1:57 AM
$KTTA is sitting near rock bottom with a tiny market cap, low float, and recent catalysts that could spark a massive re-rating. The company is advancing its PAS-004 clinical trial, expanding internationally, and strengthening its scientific advisory board signaling real biotech momentum. Trading under $1 with a prior high near $7.50, KTTA is deeply undervalued and positioned for asymmetric upside. If trial data surprises, volume surges, and sentiment shifts, this could be one of those rare small-cap biotech names that climbs back into the $20–$50+ range over time.
0 · Reply
TradeHuntFish
TradeHuntFish Sep. 19 at 2:20 AM
$MSN – No dilution, $16M cash, trading way below book value $KTTA – Biotech with bullish daily reversal forming, low float $LDI – Mortgage sector sleeper, rebounding off macro fear lows $TSLA – Holding key trendline, one strong day from breakout $INTC – Undervalued AI hardware play, earnings growth reaccelerating
0 · Reply
Shubeedoo
Shubeedoo Sep. 16 at 1:58 PM
$KTTA $LEXX running. Should/could be a 10 bagger from here. News pending, NVO, LLY?
0 · Reply
Yoety
Yoety Sep. 16 at 11:04 AM
$KTTA 💪
0 · Reply
Napoliblue
Napoliblue Sep. 13 at 4:22 AM
$KTTA this stock is dead when is the reverse split ? In the September 2025 annual meeting, shareholders approved giving the Board the authority to carry out another reverse stock split at a ratio somewhere between 1-for-2 and 1-for-20, to be executed any time before September 3, 2026, without further shareholder approval.
0 · Reply
Amcollins711
Amcollins711 Sep. 11 at 3:57 PM
$MRKR $KTTA my next two
1 · Reply
GluttonBoy
GluttonBoy Sep. 9 at 2:25 PM
TAIT stock is at zero borrow with shorts trapped and about to have a historic squeeze 3M float with no dilution and is a profitable semiconductor play $INTS $SMX $BLMZ $TGL $KTTA watching these
0 · Reply
dustbunnies
dustbunnies Sep. 9 at 8:15 AM
$KTTA have the phase 1 results been announced?
0 · Reply
TraderJay85
TraderJay85 Sep. 8 at 4:08 PM
$NXTT $AEI $KTTA $GYRO Got in early on all these and banked. small losses or big gains. thats it! thats how you make a living off the stock market. get in early, have a plan, and profit. NO discords, NO email lists, or 3 other social media platforms. Just hit the follow and we all make money together! $SWIN is my next one im in heavily on. ill see what sets up towards end of day and post another list.
0 · Reply
BioTuesdays
BioTuesdays Sep. 8 at 3:23 PM
$KTTA announced that the Safety Review Committee (SRC) has recommended its Phase 1/1b open label study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PAS-004 in adult participants with neurofibromatosis type 1 (NF1) should proceed to Cohort 2, 8mg tablet, without modification. https://biotuesdays.com/2025/09/08/pasithea-enrolls-cohort-2-for-trial-of-pas-004-in-nf1-after-src-review/
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 8 at 7:40 AM
$KTTA Excellent article that nails exactly where KTTA stands right now. So if you want to update your KTTA knowledge or get acquainted with KTTA, this is a must read. https://beyondspx.com/quote/KTTA/analysis/pasithea-therapeutics-unlocking-macrocyclic-mek-potential-amidst-funding-imperatives-nasdaq-ktta
0 · Reply
ibaian
ibaian Sep. 7 at 5:37 PM
$KTTA Pasithea Therapeutics will present at the H.C. Wainwright 27th Annual Global Investment Conference, discussing ongoing clinical trials for PAS-004 in advanced cancer patients and NF1-associated plexiform neurofibromas.
0 · Reply